{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:01:27Z","timestamp":1790791287870,"version":"4.1.0"},"reference-count":72,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ersjournals.com"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2022,10,25]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg\u2013Strauss syndrome, is a multisystem disorder characterised by asthma, blood and tissue eosinophilia and small-vessel vasculitis. Eosinophilic tissue infiltration and extravascular granuloma formation can lead to damage in any organ, but it is classically seen to cause pulmonary infiltrates, sino-nasal disease, peripheral neuropathy, renal and cardiac involvement, and rashes.<\/jats:p>\n                  <jats:p>EGPA is part of the anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis syndromes, with the antibody being detected in \u223c30\u201340% of cases and mostly against myeloperoxidase. Two genetically and clinically distinct phenotypes, defined by the presence or absence of ANCA have been identified. Treatment for EGPA focuses on inducing and maintaining disease remission. To date, oral corticosteroids remain first-line agents whilst second-line treatments include immunosuppressants such as cyclophosphamide, azathioprine, methotrexate, rituximab and mycophenolate mofetil. However, long-term steroid usage results in multiple and well-known adverse health effects and new insights into the pathophysiology of EGPA have allowed for the development of targeted biologic therapies, like the anti-eosinophilic, anti-interleukin-5 monoclonal antibodies.<\/jats:p>","DOI":"10.1183\/20734735.0170-2022","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T07:00:15Z","timestamp":1670914815000},"page":"220170","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Eosinophilic granulomatosis with polyangiitis: case report and literature review"],"prefix":"10.1183","volume":"18","author":[{"given":"Vardah","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Nanzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"2024101704051755000_18.4.220170.1","first-page":"277","article-title":"Allergic granulomatosis, allergic angiitis, and periarteritis nodosa","volume":"27","author":"Churg","year":"1951","journal-title":"Am J Pathol"},{"key":"2024101704051755000_18.4.220170.2","doi-asserted-by":"crossref","first-page":"627776","DOI":"10.3389\/fmed.2021.627776","article-title":"Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology","volume":"8","author":"Fagni","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2024101704051755000_18.4.220170.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2010.05.003"},{"key":"2024101704051755000_18.4.220170.4","doi-asserted-by":"crossref","first-page":"iii42","DOI":"10.1093\/rheumatology\/keaa089","article-title":"An update on the epidemiology of ANCA-associated vasculitis","volume":"59","author":"Mohammad","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024101704051755000_18.4.220170.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.04.022"},{"key":"2024101704051755000_18.4.220170.6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.1780330804","article-title":"Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis","volume":"33","author":"Lie","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2024101704051755000_18.4.220170.7","doi-asserted-by":"crossref","first-page":"7863815","DOI":"10.1155\/2019\/7863815","article-title":"Pulmonary manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review","volume":"2019","author":"Taweesedt","year":"2019","journal-title":"Biomed Res Int"},{"key":"2024101704051755000_18.4.220170.8","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.857582"},{"key":"2024101704051755000_18.4.220170.9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaut.2014.01.018","article-title":"Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome)","volume":"48\u201349","author":"Mouthon","year":"2014","journal-title":"J Autoimmun"},{"key":"2024101704051755000_18.4.220170.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201531"},{"key":"2024101704051755000_18.4.220170.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120808"},{"key":"2024101704051755000_18.4.220170.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.23198"},{"key":"2024101704051755000_18.4.220170.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079"},{"key":"2024101704051755000_18.4.220170.14","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00451-2020"},{"key":"2024101704051755000_18.4.220170.15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024101704051755000_18.4.220170.16","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730100-00003"},{"key":"2024101704051755000_18.4.220170.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.27678"},{"key":"2024101704051755000_18.4.220170.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes171"},{"key":"2024101704051755000_18.4.220170.19","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in health and disease: a state-of-the-art review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2024101704051755000_18.4.220170.20","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0"},{"key":"2024101704051755000_18.4.220170.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1985.tb01443.x"},{"key":"2024101704051755000_18.4.220170.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121737"},{"key":"2024101704051755000_18.4.220170.23","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2147\/JIR.S284768","article-title":"ANCA associated vasculitis subtypes: recent insights and future perspectives","volume":"15","author":"Austin","year":"2022","journal-title":"J Inflamm Res"},{"key":"2024101704051755000_18.4.220170.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12515-9"},{"key":"2024101704051755000_18.4.220170.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171352"},{"key":"2024101704051755000_18.4.220170.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.37721"},{"key":"2024101704051755000_18.4.220170.27","unstructured":"Chakraborty RK , Aeddula NR . Churg Strauss Syndrome. Treasure Island, StatPearls Publishing, 2022."},{"key":"2024101704051755000_18.4.220170.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00097-2016"},{"key":"2024101704051755000_18.4.220170.29","doi-asserted-by":"crossref","first-page":"2040622320987051","DOI":"10.1177\/2040622320987051","article-title":"Cardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors","volume":"12","author":"Liu","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"2024101704051755000_18.4.220170.30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm193"},{"key":"2024101704051755000_18.4.220170.31","doi-asserted-by":"crossref","first-page":"E1333","DOI":"10.1055\/a-0977-2777","article-title":"Gastrointestinal involvement in patients with vasculitis: IgA vasculitis and eosinophilic granulomatosis with polyangiitis","volume":"7","author":"Kawasaki","year":"2019","journal-title":"Endosc Int Open"},{"key":"2024101704051755000_18.4.220170.32","first-page":"S65","article-title":"Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides","volume":"27","author":"Zhang","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2024101704051755000_18.4.220170.33","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/j.ekir.2021.07.002","article-title":"Renal involvement in eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Doreille","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024101704051755000_18.4.220170.34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/rheumatology\/keaa416","article-title":"Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases","volume":"60","author":"Durel","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024101704051755000_18.4.220170.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.03.003"},{"key":"2024101704051755000_18.4.220170.36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.23912","article-title":"Comparison of the Birmingham vasculitis activity score and the five-factor score to assess survival in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 550 patients from Spain (REVAS registry)","volume":"72","author":"Solans-Laque","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024101704051755000_18.4.220170.37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/1756-185X.13056","article-title":"Five factor score of more than 1 is associated with relapse during the first 2 year-follow up in patients with eosinophilic granulomatosis with polyangiitis","volume":"20","author":"Kim","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2024101704051755000_18.4.220170.38","first-page":"S41","article-title":"ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center","volume":"32","author":"Sokolowska","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2024101704051755000_18.4.220170.39","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161436"},{"key":"2024101704051755000_18.4.220170.40","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"key":"2024101704051755000_18.4.220170.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221794"},{"key":"2024101704051755000_18.4.220170.42","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198403000-00001"},{"key":"2024101704051755000_18.4.220170.43","doi-asserted-by":"crossref","first-page":"858344","DOI":"10.3389\/fphar.2022.858344","article-title":"Case report: severe eosinophilic asthma associated with ANCA-negative EGPA in a young adult successfully treated with benralizumab","volume":"13","author":"Ricciardi","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024101704051755000_18.4.220170.44","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"Real world effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"2024101704051755000_18.4.220170.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2083"},{"key":"2024101704051755000_18.4.220170.46","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101704051755000_18.4.220170.47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu427"},{"key":"2024101704051755000_18.4.220170.48","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199809000-00001"},{"key":"2024101704051755000_18.4.220170.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.02.019"},{"key":"2024101704051755000_18.4.220170.50","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaip.2016.03.020","article-title":"Hypereosinophilia in children and adults: a retrospective comparison","volume":"4","author":"Williams","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101704051755000_18.4.220170.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.022"},{"key":"2024101704051755000_18.4.220170.52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fmed.2017.00216","article-title":"(A critical appraisal of) Classification of hypereosinophilic disorders","volume":"4","author":"Kahn","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"2024101704051755000_18.4.220170.53","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.854075"},{"key":"2024101704051755000_18.4.220170.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2005.08.012"},{"key":"2024101704051755000_18.4.220170.55","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90333-6"},{"key":"2024101704051755000_18.4.220170.56","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-10-200905190-00004"},{"key":"2024101704051755000_18.4.220170.57","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Puechal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024101704051755000_18.4.220170.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404231"},{"key":"2024101704051755000_18.4.220170.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802311"},{"key":"2024101704051755000_18.4.220170.60","first-page":"S52","article-title":"Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment","volume":"22","author":"Metzler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"2024101704051755000_18.4.220170.61","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00296-021-04961-w","article-title":"A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis","volume":"41","author":"Philobos","year":"2021","journal-title":"Rheumatol Int"},{"key":"2024101704051755000_18.4.220170.62","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1658"},{"key":"2024101704051755000_18.4.220170.63","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206095"},{"key":"2024101704051755000_18.4.220170.64","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","article-title":"Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis","volume":"5","author":"Thiel","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101704051755000_18.4.220170.65","doi-asserted-by":"crossref","first-page":"102737","DOI":"10.1016\/j.autrev.2020.102737","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review","volume":"20","author":"Akiyama","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2024101704051755000_18.4.220170.66","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000905"},{"key":"2024101704051755000_18.4.220170.67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40413-018-0217-0","article-title":"Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases","volume":"11","author":"Celebi Sozener","year":"2018","journal-title":"World Allergy Organ J"},{"key":"2024101704051755000_18.4.220170.68","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/art.39663","article-title":"Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): data on seventeen patients","volume":"68","author":"Jachiet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024101704051755000_18.4.220170.69","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024101704051755000_18.4.220170.70","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00311-2019"},{"key":"2024101704051755000_18.4.220170.71","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2024101704051755000_18.4.220170.72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coi.2020.10.004","article-title":"Biologic treatment options for severe asthma","volume":"66","author":"Hearn","year":"2020","journal-title":"Curr Opin Immunol"}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0170-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T07:53:06Z","timestamp":1729151586000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0170-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":72,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,13]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1183\/20734735.0170-2022"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0170-2022","relation":{},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"value":"1810-6838","type":"print"},{"value":"2073-4735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}